Jason Sanders DO , Alexandra E. Conway BA , Navya Kartha DO , Brinda Prasanna Kumar MD , John Oppenheimer MD , Marylee Verdi APRN, MSN , Aikaterini Anagnostou MD, MSc, PhD , Elissa M. Abrams MD, MPH , Karen S. Hsu Blatman MD, MBA , Matthew Greenhawt MD, MBA, MSc , Marcus S. Shaker MD, MS
{"title":"在确定非严重性食物蛋白诱发小肠结肠炎综合征的挑战设置时,共同决策的成本效益。","authors":"Jason Sanders DO , Alexandra E. Conway BA , Navya Kartha DO , Brinda Prasanna Kumar MD , John Oppenheimer MD , Marylee Verdi APRN, MSN , Aikaterini Anagnostou MD, MSc, PhD , Elissa M. Abrams MD, MPH , Karen S. Hsu Blatman MD, MBA , Matthew Greenhawt MD, MBA, MSc , Marcus S. Shaker MD, MS","doi":"10.1016/j.anai.2025.01.022","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Food protein-induced enterocolitis syndrome (FPIES) affects approximately 0.5% of US children. Oral food challenges (OFCs) are frequently conducted to assess FPIES resolution in an observed setting, given the risk of severe reactions. However, it is unclear whether the observed OFC is universally cost-effective in all contexts vs gradually titrated home OFCs when caregivers are willing to accept a risk-to-benefit tradeoff.</div></div><div><h3>Objective</h3><div>To characterize the health and economic benefits of at-home vs supervised reintroduction OFC in patients with a history of mild-moderate index FPIES.</div></div><div><h3>Methods</h3><div>Cohort analyses evaluated the cost-effectiveness of a gradually titrated home vs clinical or hospital OFC using population simulations (n = 200,000 patients) and simulations in a rural New England population (n = 105). Severe FPIES reactions were defined as necessitating intravenous fluids. Fatality rates were defined as occurring approximately in 1/1,000,000 FPIES OFCs. Motor vehicle fatality rates were applied based on the travel distance to the OFC site. The cost-effectiveness threshold was set at $10,000,000 per fatality prevented.</div></div><div><h3>Results</h3><div>In the population simulation, the supervised OFC costs reached $411,088,445, with 18,680 severe reactions occurring (per-patient mean 0.093, SD 0.025), at a cost-per-fatality prevented of $124,233,328. In a simulation of a rural New England population with FPIES, the cost per severe reaction ranged from $11,790 to $46,304.</div></div><div><h3>Conclusion</h3><div>A requirement for universally conducting FPIES challenges in an office-based or in-hospital setting is not cost-effective given extremely low FPIES reaction fatality rates, especially when compared with travel-based motor vehicle fatality rates. A shared decision-making approach may be appropriate to determine the challenge setting for patients with lower risk of severe reactions.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 6","pages":"Pages 706-712.e2"},"PeriodicalIF":5.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cost-effectiveness of shared decision-making in determining challenge setting for nonsevere food protein-induced enterocolitis syndrome\",\"authors\":\"Jason Sanders DO , Alexandra E. Conway BA , Navya Kartha DO , Brinda Prasanna Kumar MD , John Oppenheimer MD , Marylee Verdi APRN, MSN , Aikaterini Anagnostou MD, MSc, PhD , Elissa M. Abrams MD, MPH , Karen S. Hsu Blatman MD, MBA , Matthew Greenhawt MD, MBA, MSc , Marcus S. Shaker MD, MS\",\"doi\":\"10.1016/j.anai.2025.01.022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Food protein-induced enterocolitis syndrome (FPIES) affects approximately 0.5% of US children. Oral food challenges (OFCs) are frequently conducted to assess FPIES resolution in an observed setting, given the risk of severe reactions. However, it is unclear whether the observed OFC is universally cost-effective in all contexts vs gradually titrated home OFCs when caregivers are willing to accept a risk-to-benefit tradeoff.</div></div><div><h3>Objective</h3><div>To characterize the health and economic benefits of at-home vs supervised reintroduction OFC in patients with a history of mild-moderate index FPIES.</div></div><div><h3>Methods</h3><div>Cohort analyses evaluated the cost-effectiveness of a gradually titrated home vs clinical or hospital OFC using population simulations (n = 200,000 patients) and simulations in a rural New England population (n = 105). Severe FPIES reactions were defined as necessitating intravenous fluids. Fatality rates were defined as occurring approximately in 1/1,000,000 FPIES OFCs. Motor vehicle fatality rates were applied based on the travel distance to the OFC site. The cost-effectiveness threshold was set at $10,000,000 per fatality prevented.</div></div><div><h3>Results</h3><div>In the population simulation, the supervised OFC costs reached $411,088,445, with 18,680 severe reactions occurring (per-patient mean 0.093, SD 0.025), at a cost-per-fatality prevented of $124,233,328. In a simulation of a rural New England population with FPIES, the cost per severe reaction ranged from $11,790 to $46,304.</div></div><div><h3>Conclusion</h3><div>A requirement for universally conducting FPIES challenges in an office-based or in-hospital setting is not cost-effective given extremely low FPIES reaction fatality rates, especially when compared with travel-based motor vehicle fatality rates. A shared decision-making approach may be appropriate to determine the challenge setting for patients with lower risk of severe reactions.</div></div>\",\"PeriodicalId\":50773,\"journal\":{\"name\":\"Annals of Allergy Asthma & Immunology\",\"volume\":\"134 6\",\"pages\":\"Pages 706-712.e2\"},\"PeriodicalIF\":5.8000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Allergy Asthma & Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1081120625000481\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Allergy Asthma & Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1081120625000481","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
Cost-effectiveness of shared decision-making in determining challenge setting for nonsevere food protein-induced enterocolitis syndrome
Background
Food protein-induced enterocolitis syndrome (FPIES) affects approximately 0.5% of US children. Oral food challenges (OFCs) are frequently conducted to assess FPIES resolution in an observed setting, given the risk of severe reactions. However, it is unclear whether the observed OFC is universally cost-effective in all contexts vs gradually titrated home OFCs when caregivers are willing to accept a risk-to-benefit tradeoff.
Objective
To characterize the health and economic benefits of at-home vs supervised reintroduction OFC in patients with a history of mild-moderate index FPIES.
Methods
Cohort analyses evaluated the cost-effectiveness of a gradually titrated home vs clinical or hospital OFC using population simulations (n = 200,000 patients) and simulations in a rural New England population (n = 105). Severe FPIES reactions were defined as necessitating intravenous fluids. Fatality rates were defined as occurring approximately in 1/1,000,000 FPIES OFCs. Motor vehicle fatality rates were applied based on the travel distance to the OFC site. The cost-effectiveness threshold was set at $10,000,000 per fatality prevented.
Results
In the population simulation, the supervised OFC costs reached $411,088,445, with 18,680 severe reactions occurring (per-patient mean 0.093, SD 0.025), at a cost-per-fatality prevented of $124,233,328. In a simulation of a rural New England population with FPIES, the cost per severe reaction ranged from $11,790 to $46,304.
Conclusion
A requirement for universally conducting FPIES challenges in an office-based or in-hospital setting is not cost-effective given extremely low FPIES reaction fatality rates, especially when compared with travel-based motor vehicle fatality rates. A shared decision-making approach may be appropriate to determine the challenge setting for patients with lower risk of severe reactions.
期刊介绍:
Annals of Allergy, Asthma & Immunology is a scholarly medical journal published monthly by the American College of Allergy, Asthma & Immunology. The purpose of Annals is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.